Rezolute Stock: Chief Medical Officer Increases Stake in Bullish Signal

Rhea-AI Filing Summary

Insider Trading Alert: Brian Kenneth Roberts, Chief Medical Officer of Rezolute (RZLT), has acquired 2,500 common shares at a weighted average price of $4.3756 per share on June 25, 2025. The transaction was executed through multiple purchases ranging from $4.37 to $4.38 per share.

Following this transaction, Roberts' holdings include:

• Direct ownership: 172,852 common shares (15,500 + 157,352 from previous holdings)
• Indirect ownership: 1,376 shares held by minor child

This insider purchase demonstrates continued confidence in the company by a key executive. The Form 4 filing was completed within the required reporting timeframe, with the transaction executed on June 25, 2025, and reported on June 28, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROBERTS BRIAN KENNETH

(Last) (First) (Middle)

C/O REZOLUTE, INC.

275 SHORELINE DRIVE, SUITE 500

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rezolute, Inc. [ RZLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/25/2025		P		2,500	A	$4.3756(1)	15,500	D
Common Shares								157,352	D
Common Shares								1,376	I	Held by minor child

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The purchaes price reported above is a weight average price. These shares were purchased in multiple transactions at prices ranging from $4.37 to $4.38, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

	/s/ Brian Kenneth Roberts	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares of RZLT did CMO Brian Roberts purchase on June 25, 2025?

Brian Roberts, Chief Medical Officer of Rezolute (RZLT), purchased 2,500 common shares at a weighted average price of $4.3756 per share on June 25, 2025.

What is Brian Roberts' total RZLT stock ownership after the June 2025 purchase?

Following the transaction, Brian Roberts owns a total of 174,228 RZLT shares, consisting of 172,852 shares held directly (15,500 + 157,352) and 1,376 shares held indirectly through a minor child.

What was the price range of RZLT shares purchased by Brian Roberts?

The shares were purchased in multiple transactions at prices ranging from $4.37 to $4.38 per share, with a weighted average purchase price of $4.3756.

Does Brian Roberts hold any derivative securities of RZLT?

Based on Table II of the Form 4 filing, no derivative securities (such as options, warrants, or convertible securities) were reported in this transaction or held by Brian Roberts.

What positions does Brian Roberts hold at RZLT?

Brian Roberts serves as the Chief Medical Officer (CMO) of Rezolute, Inc. (RZLT), as indicated in the relationship section of the Form 4 filing.